

1 **Anti-tRNA synthetase syndrome interstitial lung disease: A single center experience**

2

3 **Authors:**

4 Erin M. Wilfong, M.D., Ph.D.^{1,2†}, ORCID ID 0000-0002-6584-1578

5 Jennifer J. Young-Glazer, M.D., M.S.C.I.², ORCID ID 0000-0002-3265-9112

6 Bret K. Sohn, MD²

7 Gabriel Schroeder, M.D.³

8 Narender Annapureddy, M.D.², ORCID ID 0000-0002-4012-3406

9 Erin A. Gillaspie, M.D.⁴, ORCID ID 0000-0003-2075-5534

10 April Barnado, M.D., M.S.C.I.², ORCID ID 0000-0002-9573-4335

11 Leslie J. Crofford, M.D.², ORCID ID 0000-0002-6347-5738

12 Rosemarie Beckford Dudenhofer, M.D.¹

13

14 **Affiliations:**

15 ¹Vanderbilt University Medical Center, Department of Medicine, Division of Allergy, Pulmonary, and
16 Critical Care Medicine, Nashville, TN, 37232, USA

17 ²Vanderbilt University Medical Center, Department of Medicine, Division Rheumatology and
18 Immunology, Nashville, TN, 37232, USA

19 ³Vanderbilt University Medical Center, Department of Medicine, Nashville, TN, 37232, USA

20 ⁴Vanderbilt University Medical Center, Department of Thoracic Surgery, Nashville, TN 37232

21

22 †Corresponding Author:

23 Erin M. Wilfong, M.D., Ph.D.

24 1161 21st Ave So., MCN T-1218

25 Nashville, TN 37232

26 Phone: (615) 936-5747

27 Fax: (615) 322-6248

28 Email: erin.m.wilfong@vumc.org

29 **Abstract:**

30 **Background:** Recognition of Anti tRNA synthetase (ARS) related interstitial lung disease (ILD) is key
31 to ensuring patients have prompt access to immunosuppressive therapies. The purpose of this
32 retrospective cohort study was to identify factors that may delay recognition of ARS-ILD.

33 **Methods:** Patients seen at Vanderbilt University Medical Center (VUMC) between 9/17/2017-
34 10/31/2018 were included in this observational cohort. Clinical and laboratory features were obtained
35 via chart abstraction. Kruskal-Wallis ANOVA, Mann-Whitney U, and Fisher's exact t tests were utilized
36 to determine statistical significance.

37 **Results:** Patients with ARS were found to have ILD in 51.9% of cases, which was comparable to the
38 frequency of ILD in systemic sclerosis (59.5%). The severity of FVC reduction in ARS (53.2%) was
39 comparable to diffuse cutaneous systemic sclerosis (56.8%, $p=0.48$) and greater than dermatomyositis
40 (66.9%, $p=0.005$) or limited cutaneous systemic sclerosis (lcSSc, 71.8%, $p=0.005$). Frank
41 honeycombing was seen with ARS antibodies but not other myositis autoantibodies. ARS patients were
42 more likely to first present to a pulmonary provider in a tertiary care setting (53.6%), likely due to fewer
43 extrapulmonary manifestations. Only 33% of ARS-ILD were anti-nuclear antibody, rheumatoid factor,
44 or anti-cyclic citrullinated peptide positive. Patients with ARS-ILD had a two-fold longer median time to
45 diagnosis compared to other myositis-ILD patients (11.0 months, IQR 8.5 to 43 months vs. 5.0 months,
46 IQR 3.0 to 9.0 months, $p=0.003$).

47 **Conclusions:** ARS patients without prominent extra-pulmonary manifestations are at high risk for not
48 being recognized as having a connective tissue disease related ILD and miscategorized as UIP/IPF
49 without comprehensive serologies.

50 **Keywords:**

51 Idiopathic inflammatory myopathies

52 Anti-tRNA synthetase syndrome

53 Systemic sclerosis

54 Connective tissue disease related interstitial lung disease

55 Usual interstitial pneumonia

56

57 Recognition of idiopathic inflammatory myopathy (IIM) spectrum disease is challenging due
58 phenotypic heterogeneity. While the original Bohan and Peter criteria focused on classic skin rashes
59 and muscle weakness [1], there has been increasing recognition that these clinical classifications
60 oversimplify marked heterogeneity and that myositis autoantibodies are associated with a variety of
61 classical clinical presentations (table 1). Interstitial lung disease is particularly prevalent in the anti-
62 tRNA synthetase syndrome (ARS), which classically presents with the triad of arthritis, interstitial lung
63 disease, and mechanic's hands. Amongst ARS antibodies, however, the frequency of skin, muscle,
64 and lung disease is variable. Patients with anti-Jo-1 antibodies are more likely to have joint and muscle
65 involvement; non-Jo-1 positive patients are more likely to have vascular and cutaneous involvement [2].
66 Patients with anti-PL7 and anti-PL12 antibodies have more severe pulmonary manifestations [3].

67 The diagnosis of IIM-ILD remains a challenge. Presently, the American Thoracic Society
68 recommends that CTD-ILD be ruled out clinically and with basic serologic screening (anti-nuclear
69 antibodies (ANA), rheumatoid factor (RF), and anti-cyclic citrullinated antibodies (CCP)), but does not
70 recommend comprehensive myositis serologies [4]. However, not only are basic serologies more apt to
71 be negative in IIM compared other connective tissue diseases, but IIM patients are also less likely to
72 fulfil clinical connective tissue disease (CTD) classification criteria. For example, nearly all patients with
73 SSc-ILD will have a positive ANA, and the clinical classification criteria for SSc have >95% sensitivity in
74 external validation cohorts [5]. In contrast, fewer than 50% of ARS patients have a positive ANA [6],
75 and external validation of the 2017 American College of Rheumatology and European League Against
76 Rheumatism (ACR/EULAR) classification criteria for idiopathic inflammatory myopathies cohorts has
77 yielded sensitivities as low as 71% [7]. For non-Jo1 associated ARS, the sensitivity of the 2017
78 ACR/EULAR classification criteria is as low as 25% [8]. This low sensitivity has led to the ACR/EULAR
79 funding the CLASS (classification criteria of antisynthetase syndromes) project to develop improved
80 criteria to diagnose of ARS [9].

81 The goal of this retrospective cohort study was to (1) evaluate the clinical, radiographic, and
82 serologic features of ARS compared to other patients with IIM and SSc, and (2) gain insights into

83 possible etiologies leading to delayed diagnosis and therapy in the ARS subgroup. We hypothesize
84 that ARS patients will have more subtle clinical and laboratory findings compared to other subsets of
85 IIM-ILD and SSc-ILD despite an equivalent physiologic severity of ILD.

86

87 **Patients and Methods**

88 *Patient Identification*

89 Institutional Review Board approval was obtained. Patients were identified from either the Myositis
90 and Scleroderma Treatment Initiative Center (MYSTIC) cohort or the ILD in Autoimmune Inflammatory
91 Myopathy Cohort (IAIMC). Patients with suspected systemic sclerosis, idiopathic inflammatory
92 myopathies, mixed connective tissue disease, or interstitial pneumonia with autoimmune features were
93 eligible for referral to the MYSTIC cohort by their treating provider in the outpatient pulmonary, thoracic
94 surgery, or rheumatology clinic, the inpatient rheumatology or pulmonary consulting service, or by their
95 critical care provider in the intensive care unit (VUMC IRB 141415) from September 20, 2017-
96 December 31, 2019. As MYSTIC is a longitudinal convenience cohort, additional patients were
97 identified through the electronic medical record (VUMC IRB 180672) using a keyword search of the
98 following: “dermatomyositis”, “polymyositis”, “anti-synthetase syndrome”, “systemic sclerosis” in any
99 Vanderbilt Rheumatology or Pulmonology affiliated practice visit between July 1, 2018-October 31,
100 2018. Exclusion criteria included prior inclusion in the MYSTIC cohort and myositis attributed to
101 medications, infection, or another rheumatologic condition (e.g. mixed connective tissue disease.
102 Diagnoses were verified by review of progress notes, laboratory findings, and scanned documents.

103

104 *Clinical phenotyping*

105 Clinical phenotyping was performed by chart abstraction to identify date of symptom onset, skin
106 manifestations (digital ulceration/pitting, mechanic’s hands, Gottron’s sign/papules, heliotrope rash,
107 shawl sign, skin ulcerations), Raynaud’s phenomenon, inflammatory arthritis, pulmonary manifestations
108 (ILD, pulmonary arterial hypertension), myocarditis, muscle weakness, esophageal dysmotility and/or

109 reflux. Serologic data collected included ANA titer and pattern, RF, anti-CCP, and comprehensive
110 myositis serologies (Jo-1, PL-7, PL-12, EJ, OJ, SRP, Mi-2, P155/140, Tif-1 γ , SAE1, MDA-5, NXP-2,
111 Ro52, Ro60, Pm/ScI-100, U3RNP, U2RNP through ARUP, Salt Lake, UT). Data on cytoplasmic ANA
112 antibodies was not routinely available. Laboratory values for creatinine kinase (CK) were recorded
113 when available. Patients with dermatomyositis or polymyositis met the 2017 ACR/EULAR classification
114 criteria for probable or definite dermatomyositis or polymyositis [10]. Patients with ARS met the diagnostic
115 criteria proposed by Connors et al. [11] but were not required to meet the 2017 IIM classification
116 criteria. SSc patients met the 2013 classification criteria [12]. When documenting first point of contact
117 at VUMC, patients presenting to thoracic surgery were classified as having presented to a pulmonary
118 provider. Basic demographic data such as age, self-identified gender, and self-identified race/ethnicity
119 were also collected.

120

121 *Pulmonary phenotyping*

122 Pulmonary phenotyping was performed using chart abstraction and analysis of computerized
123 tomography (CT) scans, chest x-ray, PFTs, echocardiogram, right heart catheterization (RHC), and
124 pathology reports. Patients were classified as having interstitial lung disease if the radiologist reading
125 the clinical CT scan determined that fibrosis or interstitial lung disease was present on CT scan or chest
126 x-ray if CT was unavailable. The severity of restriction or reduction in DLCO was graded as mild (65-
127 79% predicted), moderate (50-64% predicted) or severe (<50% predicted) using the worst available
128 PFT value. Patients were classified as having pulmonary hypertension if an echocardiogram
129 demonstrated RVSP > 40 mmHg or mean PA pressure on RHC >25 mmHg. RHC was considered gold
130 standard in cases of conflicting data. CT reports were analyzed for mention of honeycombing,
131 bronchiectasis, or ground glass opacities. Radiographic classifications of ILD, e.g. usual interstitial
132 pneumonia (UIP), atypical for UIP, nonspecific interstitial pneumonia (NSIP), and organizing pneumonia
133 (OP) as determined by the reading radiologist was recorded. Patients for whom no CT or PFTs were
134 obtained were assumed to have no or mild ILD [13, 14].

135

136 *Statistics*

137 All available cases were analyzed. Bias was minimized through blinding during chart abstractions.
138 Missing data was addressed through pairwise deletion. Categorical variables were analyzed using
139 Fisher's exact test through the GraphPad Quick Calcs Web site: <http://www.graphpad.com/quickcalcs/>
140 (accessed November 2020). Differences in continuous variables were tested using Kruskal-Wallis
141 ANOVA for multiple comparisons followed by Mann-Whitney U tests for comparisons between groups
142 in GraphPad Prism v.7.04. All analyses were two-tailed, and *p values* of less than 0.05 were
143 considered statistically significant. Data is reported as the average \pm standard error of the mean unless
144 otherwise noted.

145

146 **Results**

147 *Demographics*

148 Demographic characteristics are shown in Table 2. One hundred twenty-five patients were
149 included in the study; one patient was excluded due to conflicting historical reports regarding the
150 presence of ILD and the lack of any PFTs or CT scans. Eighty-four patients (20 DM, 4 PM, 16 ARS, 14
151 dcSSc, 30 lcSSc) were included from the prospective MYSTIC cohort; 40 unique patients were included
152 from electronic IAIMC cohort (17 DM, 8 PM, 12 ARS, 2 dcSSc, 1 lcSSc). Subjects were predominantly
153 female (77.9% IIM, 78.7% SSc) and Caucasian (81.8% IIM, 78.7% SSc). Median disease duration was
154 estimated from the first report of symptom onset to cohort enrolment and was 5.2 years for IIM versus
155 9.5 years in SSc ($p=0.007$).

156

157 *Clinical phenotypes in IIM*

158 Clinical characteristics of IIM patients are shown in Table 3. Thirty-seven patients (48.1%) were
159 classified as DM, 12 (15.5%) were classified as PM, and 28 (36.4%) were diagnosed as ARS.
160 Subjective proximal muscle weakness was less common in ARS (64.3%) than PM (100%, $p=0.002$) but

161 not DM (73.0%, p=0.09). There was no difference in the frequency of muscle enzyme elevation in ARS
162 (75.0%) compared to DM (78.3%, p=0.77) or PM (91.7%, p=0.40). Dysphagia or GERD was present in
163 46.4% of ARS patients, which was not statistically different from DM (29.8%, p=0.20) or PM (66.7%,
164 p=0.31). Inflammatory arthritis was noted in 60.7% of ARS patients, which is higher than either DM
165 (27.0%, p=0.01) or PM (8.3%, p=0.004). By convention, cutaneous manifestations are absent in
166 polymyositis. There was a lower prevalence of Gottron's sign/papules or heliotrope rash in ARS
167 compared to DM (21.4% v. 89.1%, p=0.0001). There was no difference in prevalence between ARS
168 and DM of mechanic's hands (43.8% v. 24.3%, p=0.18) or Raynaud's phenomenon (37.8% v. 35.7%,
169 p=1.0).

170 Known interstitial lung disease was present in 51.9% of IIM patients. Chest CT scans were
171 available for all but two IIM-ILD patients. ILD was more frequently seen in ARS (78.5%) than in
172 dermatomyositis (40.5%, p=0.00263) or polymyositis (25.0%, p=0.003). In this cohort, all patients with
173 PL-7, PL-12, or EJ antibodies had interstitial lung disease; 80% of Jo-1 positive patients had ILD.
174 Patients with Mi-2 associated dermatomyositis had the lowest frequency of ILD with only 20.0% having
175 known ILD.

176 Serologically, only 36% of ARS patients were ANA positive compared to 80.6% of DM patients
177 (p=0.004) and 60% of PM patients (p=0.45). Ro52 positivity was observed with similar frequency in
178 ARS and DM (63.6% v.40.0%, p=1.00) but no PM patient was Ro52 positive. There was no statistically
179 significant difference in the frequency of RF positivity.

180

181 *Patients with ARS-ILD frequently present to pulmonary providers at a tertiary center*

182 Of ARS patients, 53.6% presented first to pulmonary providers, which is significantly higher than
183 DM (16.2%, p=0.003) or PM (8.3%, p=0.01). There was no difference in the likelihood of Jo-1 or non-
184 Jo1 associated ARS to present first to a pulmonary provider (60.0% v. 75.0%, p=0.65). Of the 15
185 patients with ARS-ILD who presented initially to pulmonology, 80% of patients had been seen by
186 outside pulmonologists and 40% by outside rheumatologists. Only one had received the correct

187 diagnosis of ARS-ILD prior to tertiary referral. The time from symptom onset to diagnosis could be
188 abstracted for 21/22 ARS-ILD patients, 11/15 DM-ILD patients, and 3/3 PM-ILD patients. Patients with
189 ARS-ILD had a longer median time to diagnosis (11.0 months, IQR 8.5 to 43 months) than other IIM-
190 ILD subsets (5.0 months, IQR 3.0 to 9.0, $p=0.003$). (Figure 1) There was a trend towards ARS-ILD
191 patients presenting to pulmonary clinic being less likely to meet IIM classification criteria, but this did
192 not reach significance (66.7% v. 85.8%, $p=0.6158$).

193 Many pulmonary providers will screen for CTD-ILD using an ANA, RF, and anti-CCP antibodies.
194 The efficacy of detecting a potential CTD-ILD with a basic serologic assessment using ANA, RF, and
195 anti-CCP testing is shown in table 4. Patients with ARS-ILD were much less likely to be identified using
196 this strategy than DM-ILD (33.3% v. 86.7%, $p=0.002$). If a CK was also obtained, the likelihood of
197 detecting a possible CTD-ILD increased to 72.7% for ARS-ILD compared to 86.7% for DM-ILD
198 ($p=0.43$). Statistical comparisons to PM-ILD were precluded due to small sample size. Myositis
199 specific serologies were required to detect the final 27.3% of patients with ARS-ILD.

200

201 *Radiographic features of ARS-ILD*

202 Radiographic features of IIM and SSc associated ILD are shown in table 5. Due to the paucity of
203 PM-ILD, these were excluded from statistical comparisons. Notably, only patients with anti-tRNA
204 synthetase antibodies (22.7%) had CT scans that were read by a radiologist as compatible with usual
205 interstitial pneumonia (UIP); no patient a non-anti-tRNA synthetase antibody had a CT scan compatible
206 with UIP. The solitary patient with clinical dermatomyositis and a UIP pattern CT scan did not have
207 comprehensive myositis serologies. Patients with UIP pattern CT scans ranged in age from 49.2 to
208 70.8 years of age and there was a trend towards the median age of UIP-pattern patients being older
209 than non-UIP pattern patients (63.3, IQR 54.8,70.8 yrs., v. 55.2, IQR 46.8,60.6 yrs., $p=0.09$).
210 Bronchiectasis trended towards being more prevalent in ARS compared to other IIM subsets (50% v.
211 22.2%, $p=0.10$). Of ARS patients, 13.6% had frank honeycombing, which was not seen an any other

212 IIM subset. There was no difference in the frequency of ground glass abnormalities between ARS and
213 other IIM patients.

214

215 *Physiologic features of ARS-ILD.*

216 Physiologic features of IIM- and SSc-ILD are shown in Figures 2 and 3. Due to the paucity of PM
217 patients with ILD, these were again excluded from subgroup statistical analyses. Overall, patients with
218 IIM and SSc had comparable restriction (60.3% v. 66.6% predicted FVC, $p=0.15$) and diffusion
219 impairment (48.0% v. 51.1% predicted DLCO, $p=0.63$). However, ARS-ILD demonstrated more severe
220 reduction in FVC (53.2% predicted) than patients with DM (66.9% predicted, $p=0.005$) or lcSSc (71.8%
221 predicted, $p=0.005$). The severity of ARS and dcSSc-ILD was comparable (53.2% v. 56.8% predicted
222 FVC, $p=0.48$). Similarly, patients with ARS were more likely to have a severe diffusion impairment
223 (e.g. <50% predicted) than in DM (54.5% v. 6.7%, $p=0.004$) but not dcSSc (54.5% v. 30.0%, $p=0.27$).
224 While there was a trend towards worsening impairment of diffusion in ARS relative to DM (39.8% v.
225 48.0% predicted DLCO, $p=0.08$) and dcSSc (39.8% v. 51.4% predicted DLCO, $p=0.13$), this did not
226 reach statistical significance. There was no difference in the severity of restriction or diffusion
227 impairment ARS-ILD patients with positive vs. negative Jo-1 antibodies.

228

229 **Discussion**

230 Our primary findings can be summarized as following, (1) patients with ARS have a high frequency
231 of interstitial lung disease with more severe restriction than other IIM subsets (2) radiographic UIP was
232 observed only in patients with ARS-ILD in this cohort, (3) patients with ARS are frequently referred to a
233 tertiary center after seeing a local pulmonologist and/or rheumatologist without receiving the correct
234 diagnosis, and (4) patients with ARS-ILD have a delayed diagnosis compared to DM-ILD and PM-ILD.

235 Improving recognition of ARS-ILD is key to ensuring these patients have prompt access to
236 immunosuppressive therapies. Diagnostic delays in ARS are well described and are known to be an
237 independent risk factor for mortality in ARS-ILD [2]. Cavagna et al. described Jo-1 positive patients

238 who presented without the classic triad of arthritis, myositis, and interstitial lung disease had a trend
239 towards increased median time to diagnosis from 2.5 to 10 months [15]. While delays in ARS-ILD
240 diagnosis are frequently discussed in the literature, to our knowledge this is the first report to quantify a
241 delay in diagnosis in ARS-ILD compared to other IIM-ILD. Given that nearly 25% of ARS patients
242 present first with ILD [2], decreasing the diagnostic delay is critical.

243 The frequency with which ARS-ILD presents with UIP radiographically further complicates
244 recognition of ARS-ILD. In our cohort, 22.7% of patients had CT scans read as compatible with UIP.
245 While ARS-UIP may be enriched at an academic center, it has previously been recognized that most
246 IIM-UIP is associated with ARS. Of the 43 patients in the Pittsburgh cohort with biopsy proven UIP,
247 only one did not have ARS [16]. Using the 2013 Fleischner Society guidelines, a cohort of 69 Chinese
248 ARS-ILD patients identified that 8.7% had a high resolution CT scan classified as UIP [17]. A second
249 longitudinal study of serial CT scans in ARS-ILD found that while 100% of patients had some ground
250 glass at diagnosis, subsequent scans showed the ground glass decreased in 38%. Additionally, 42%
251 of patients had honeycombing and 50% had worsening traction bronchiectasis at follow-up [18]. The
252 prevalence of honeycombing and traction bronchiectasis in ARS may lead to radiographic classification
253 as UIP on CT scans, especially in the community setting. The 2018 American Thoracic Society
254 guidelines for diagnosing idiopathic pulmonary fibrosis allow patients with ground-glass opacities to be
255 classified as UIP in the absence of other clear etiologies and so long as the ground-glass opacities are
256 not the predominant radiographic feature [4]. Thus, ARS patients without prominent extra-pulmonary
257 manifestations are at high risk for not being recognized as having an alternative etiology and
258 miscategorized as UIP/IPF in the absence of comprehensive serologies.

259 In our cohort, only 33% of patients were identified on basic screening serologies to have signs of a
260 connective tissue disease. While this is slightly lower than some prior studies [6, 17], a substantial
261 number of ARS patients are ANA, RF, and anti-CCP negative in all cohorts. Additionally, there is
262 increasing evidence that obtaining comprehensive serologies and engaging rheumatology improves the
263 care of ILD patients. Nakashima et al. evaluated the ARS serology status of 168 patients with

264 idiopathic interstitial pneumonia and found that 10.7% were positive for an anti-tRNA synthetase
265 antibody, including 5.3% of patients who were diagnosed as IPF [19]. Another study found that even a
266 modest expansion of routine serologies and inclusion of a rheumatologist in the multi-disciplinary ILD
267 team resulted in 21% of IPF patients being re-classified as having an autoimmune process and eight
268 invasive diagnostic procedures were avoided [20]. This study further highlights the importance of using
269 expanded serologies to aid in the identification of IIM-ILD generally and ARS-ILD specifically.

270 Prompt recognition of ARS-ILD is imperative as immunosuppression is efficacious in ARS-ILD.
271 Previous work by Danoff and co-workers demonstrated that patients with IIM-ILD have an improvement
272 in their FVC following treatment with immunosuppressive therapy [21]. A post-hoc analysis of the
273 rituximab in myositis phase III clinical trial [22] indicated a benefit in ARS-ILD. Efficacy for tacrolimus in
274 both naïve [23] and refractory IIM-ILD [24] has also been reported. Even patients with myositis related
275 usual interstitial pneumonia, which is nearly always ARS-ILD, have a slower rate of FVC decline and
276 improved mortality compared with IPF patients after treatment with immunosuppression [16]. However,
277 if a patient is not recognized to have ARS-ILD, they may not gain access to critically needed
278 immunosuppressive agents. For this reason, we continue to advocate for the use of comprehensive
279 serologies in the evaluation of new patients with interstitial lung disease and the inclusion of
280 rheumatologists as part of the multi-disciplinary team discussion of ILD patients.

281 This study has several limitations. First, a cross-sectional design at a single center resulted in a
282 limited sample size, which precluded comparisons between some IIM-ILD groups. Additionally, not all
283 CT scans used in this study were high-resolution, which is considered gold standard for the
284 classification of ILD patterns. Further, the use of retrospective chart abstractions meant that not all
285 patients had a complete dataset, and data on objective muscle weakness across the entire clinical
286 course was not available. While comprehensive myositis serologies are clearly useful for identifying
287 ARS-ILD, the yield of comprehensive myositis screening in a tertiary ILD clinic is unclear.

288 In conclusion, ARS patients without prominent extra-pulmonary manifestations are at high risk for
289 not being recognized as having an alternative etiology and miscategorized as UIP/IPF in the absence of

290 comprehensive serologies. Future work is required to (1) quantify the benefit instituting comprehensive
291 serologies and rheumatologic consultation in the care of ILD patients at a tertiary care center and (2)
292 determine if obtaining comprehensive myositis serologies improves patient outcomes.

293

294 **Acknowledgements:** This work was supported by CTSA award No. UL1TR000445 (EMW) from the
295 National Center for Advancing Translational Sciences, the National Institutes of Health T32HL087738
296 (EMW), T32AR0590139 (JJY), K08AR072757 (AB), Vanderbilt Faculty Research Scholars Award
297 (EMW), and the Porter Family Fund for Autoimmunity Research. The contents are solely the
298 responsibility of the authors and do not necessarily represent official views of the National Center for
299 Advancing Translational Sciences or the National Institutes of Health.

300

301

302 **References**

- 303 1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). *N Engl J Med* 1975:
304 292(7): 344-347.
- 305 2. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, Oddis CV. Patients with
306 non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. *Ann*
307 *Rheum Dis* 2014; 73(1): 227-232.
- 308 3. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, Silhan L,
309 Christopher-Stine L, Mammen AL, Danoff SK. A longitudinal cohort study of the anti-synthetase
310 syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and
311 anti-PL12 autoantibodies. *Rheumatology (Oxford)* 2017; 56(6): 999-1007.
- 312 4. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V,
313 Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK,
314 Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL,
315 Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson
316 KC, American Thoracic Society ERSJRS, Latin American Thoracic S. Diagnosis of Idiopathic
317 Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care*
318 *Med* 2018; 198(5): e44-e68.
- 319 5. Hoffmann-Vold A-M, Gunnarsson R, Garen T, Midtvedt Ø, Molberg Ø. Performance of the 2013
320 American College of Rheumatology/European League Against Rheumatism Classification Criteria for
321 Systemic Sclerosis (SSc) in Large, Well-defined Cohorts of SSc and Mixed Connective Tissue Disease.
322 *The Journal of Rheumatology* 2015; 42(1): 60-63.
- 323 6. Aggarwal R, Dhillon N, Fertig N, Koontz D, Qi Z, Oddis CV. A Negative Antinuclear Antibody
324 Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening
325 Test for Antisynthetase Syndrome. *J Rheumatol* 2017; 44(2): 223-229.

- 326 7. Luu Q, Day J, Hall A, Limaye V, Major G. External Validation and Evaluation of Adding MRI or
327 Extended Myositis Antibody Panel to the 2017 EULAR/ACR Myositis Classification Criteria. *ACR Open*
328 *Rheumatology* 2019; 1(7): 462-468.
- 329 8. Greco M, García de Yébenes MJ, Alarcón I, Brandy-García AM, Rúa-Figueroa Í, Loza E,
330 Carmona L. Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of
331 antisynthetase antibodies to improve current classification criteria. *Annals of the Rheumatic Diseases*
332 2019; 78(9): 1291-1292.
- 333 9. Knitza J, Cavagna L, Schett G, Distler JHW. Comment on: 'Idiopathic inflammatory myopathies
334 and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification
335 criteria' by Greco *et al*. *Annals of the Rheumatic Diseases* 2020; 79(7): e85-e85.
- 336 10. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA,
337 Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K,
338 Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA,
339 Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A,
340 Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, International Myositis Classification Criteria
341 Project consortium TEr, The Juvenile Dermatomyositis Cohort Biomarker S, Repository. 2017
342 European League Against Rheumatism/American College of Rheumatology classification criteria for
343 adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Ann Rheum Dis*
344 2017; 76(12): 1955-1964.
- 345 11. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with
346 the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? *Chest*
347 2010; 138(6): 1464-1474.
- 348 12. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M,
349 Naden RP, Medsger TA, Jr., Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O,
350 Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M,
351 Kowal-Bielecka O, Muller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH,

352 Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski
353 S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an
354 American College of Rheumatology/European League against Rheumatism collaborative initiative.
355 *Arthritis Rheum* 2013; 65(11): 2737-2747.

356 13. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in
357 patients with interstitial lung disease. *Chest* 1999; 116(5): 1175-1182.

358 14. Papis SA, Daniil ZD, Malagari K, Kapotsis GE, Sotiropoulou C, Milic-Emili J, Roussos C. The
359 Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary
360 fibrosis. *Respir Med* 2005; 99(6): 755-761.

361 15. Cavagna L, Nuno L, Scire CA, Govoni M, Longo FJ, Franceschini F, Neri R, Castaneda S,
362 Sifuentes Giraldo WA, Caporali R, Iannone F, Fusaro E, Paolazzi G, Pellerito R, Schwarting A,
363 Saketkoo LA, Ortego-Centeno N, Quartuccio L, Bartoloni E, Specker C, Murcia TP, La Corte R, Furini
364 F, Foschi V, Corral JB, Airo P, Cavazzana I, Martinez-Barrio J, Hinojosa M, Giannini M, Barsotti S,
365 Menke J, Triantafyllias K, Vitetta R, Russo A, Bajocchi G, Bravi E, Barausse G, Bortolotti R, Selmi C,
366 Parisi S, Montecucco C, Gonzalez-Gay MA, group Ac. Clinical Spectrum Time Course in Anti Jo-1
367 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study.
368 *Medicine (Baltimore)* 2015; 94(32): e1144.

369 16. Aggarwal R, McBurney C, Schneider F, Yousem SA, Gibson KF, Lindell K, Fuhrman CR, Oddis
370 CV. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary
371 fibrosis. *Rheumatology (Oxford)* 2017; 56(3): 384-389.

372 17. Liu H, Xie S, Liang T, Ma L, Sun H, Dai H, Wang C. Prognostic factors of interstitial lung
373 disease progression at sequential HRCT in anti-synthetase syndrome. *European Radiology* 2019;
374 29(10): 5349-5357.

375 18. Debray MP, Borie R, Revel MP, Naccache JM, Khalil A, Toper C, Israel-Biet D, Estellat C, Brillet
376 PY. Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. *Eur J Radiol*
377 2015; 84(3): 516-523.

- 378 19. Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, Handa T, Mishima M,
379 Hirakata M, Takeuchi T, Fujio K, Yamamoto K, Kohsaka H, Takasaki Y, Enomoto N, Suda T, Chida K,
380 Hisata S, Nukiwa T, Mimori T. The multicenter study of a new assay for simultaneous detection of
381 multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. *PLoS One* 2014; 9(1):
382 e85062.
- 383 20. Levi Y, Israeli-Shani L, Kuchuk M, Epstein Shochet G, Koslow M, Shitrit D. Rheumatological
384 Assessment Is Important for Interstitial Lung Disease Diagnosis. *The Journal of Rheumatology* 2018:
385 45(11): 1509-1514.
- 386 21. Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ,
387 Sanyal A, Mammen AL, Christopher-Stine L, Danoff SK. Long-Term Treatment With Azathioprine and
388 Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. *Chest* 2019; 156(5): 896-906.
- 389 22. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider
390 LG, Harris-Love MO, Levesque MC, Group RIMS, Oddis CV. Predictors of clinical improvement in
391 rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. *Arthritis*
392 *Rheumatol* 2014; 66(3): 740-749.
- 393 23. Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, Fujieda Y, Oku K, Bohgaki T,
394 Amengual O, Horita T, Atsumi T. The efficacy of tacrolimus in patients with interstitial lung diseases
395 complicated with polymyositis or dermatomyositis. *Rheumatology (Oxford)* 2015; 54(1): 39-44.
- 396 24. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of
397 antisynthetase-associated interstitial lung disease with tacrolimus. *Arthritis & Rheumatism: Official*
398 *Journal of the American College of Rheumatology* 2005; 52(8): 2439-2446.
- 399 25. Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, Roblot P, Jouneau S, Hatron PY,
400 Tiev KP, Vittecoq O, Noel D, Mouthon L, Menard JF, Jouen F. Comparison of long-term outcome
401 between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. *Autoimmunity*
402 *Reviews* 2012; 11(10): 739-745.

- 403 26. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-
404 isoleucyl-tRNA synthetase) autoantibodies. *Rheumatology* 2007; 46(5): 842-845.
- 405 27. Carlos de Souza FH, Pina Cruellas MG, Levy-Neto M, Shinjo SK. Anti-synthetase syndrome:
406 anti-PL-7, anti-PL-12 and anti-EJ. *Revista Brasileira de Reumatologia (English Edition)* 2013; 53(4):
407 352-357.
- 408 28. Giannini M, Notarnicola A, Dastmalchi M, Lundberg IE, Lopalco G, Iannone F. Heterogeneous
409 clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case
410 series. *Clinical Rheumatology* 2016; 35(9): 2363-2367.
- 411 29. Schneider F, Yousem SA, Bi D, Gibson KF, Oddis CV, Aggarwal R. Pulmonary pathologic
412 manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy. *Journal of*
413 *Clinical Pathology* 2014; 67(8): 678-683.
- 414 30. Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramírez R, Jara LJ, Saavedra MA, Cruz-
415 Gonzalez C, Andrade-Ortega L, Vera-Lastra O, Salazar-Páramo M, Prieto-Parra RE, Gonzalez-Lopez
416 L, Gamez-Nava JI, Ramírez-Sánchez HU, Chan JYF, Ross SJ, Chan EKL, Vázquez-Del Mercado M.
417 Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two
418 dermatomyositis cohorts from Mexico City and Guadalajara. *Arthritis Research & Therapy* 2013; 15(2):
419 R48.
- 420 31. Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK,
421 Johnson C, Christopher-Stine L, Mammen AL. Antinuclear Matrix Protein 2 Autoantibodies and Edema,
422 Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. *Arthritis Care & Research* 2017;
423 69(11): 1771-1776.
- 424 32. Yang H, Lu X, Peng Q, Jiang W, Shi J, Zhang Y, Chen H, Wang G. Differential Clinical
425 Associations of Anti-Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory
426 Myopathies. *Arthritis & Rheumatology* 2018; 70(8): 1288-1297.
- 427 33. Cuesta-Mateos C, Colom-Fernández B, Portero-Sainz I, Tejedor R, García-García C, Concha-
428 Garzón MJ, De las Heras-Alonso ME, Martínez MA, Juárez C, Muñoz-Calleja C. Autoantibodies against

429 TIF-1- γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical
430 significance and diagnostic utility. *Journal of the European Academy of Dermatology and Venereology*
431 2015; 29(3): 482-489.

432 34. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WER, Cooper RG, McHugh NJ.
433 Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small
434 ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-
435 onset myositis. *Annals of the Rheumatic Diseases* 2009; 68(10): 1621-1625.

436 35. Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik JJ, Danoff SK, Casciola-Rosen L,
437 Christopher-Stine L, Mammen AL. Longitudinal Course of Disease in a Large Cohort of Myositis
438 Patients With Autoantibodies Recognizing the Signal Recognition Particle. *Arthritis Care & Research*
439 2017; 69(2): 263-270.


440 36. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma Differentiation-
441 associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with
442 Dermatomyositis. *The Journal of Rheumatology* 2017; 44(3): 319-325.

443 37. Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airò P, Cattaneo R, Franceschini F.
444 Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. *Lupus*
445 2008; 17(8): 727-732.

446 38. Casal-Dominguez M, Pinal-Fernandez I, Corse AM, Paik J, Albayda J, Casciola-Rosen L,
447 Johnson C, Danoff SK, Christopher-Stine L, Tiniakou E, Mammen AL. Muscular and extramuscular
448 features of myositis patients with anti-U1-RNP autoantibodies. *Neurology* 2019; 92(13): e1416-e1426.

449 39. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger Jr. TA. Anti-U3 RNP autoantibodies in
450 systemic sclerosis. *Arthritis & Rheumatism* 2009; 60(4): 1112-1118.

451 40. De Lorenzo R, Pinal-Fernandez I, Huang W, Albayda J, Tiniakou E, Johnson C, Milisenda JC,
452 Casal-Dominguez M, Corse AM, Danoff SK, Christopher-Stine L, Paik JJ, Mammen AL. Muscular and
453 extramuscular clinical features of patients with anti-PM/Scl autoantibodies. *Neurology* 2018; 90(23):
454 e2068-e2076.





455

456 **Figure 1.** Time to diagnosis for patients with ARS-ILD (n=21) compared to DM/PM-ILD (n=14). Violin

457 plots show the range with interquartile range. Mann-Whitney U-tests shown.


458



459

460 **Figure 2.** Physiologic features of IIM-ILD compared to SSc-ILD. (A) Patients with ARS have more
 461 severe restriction than DM or lcSSc and similar restriction compared to dcSSc. (B) There is no
 462 significant difference in diffusion impairment amongst IIM or SSc subsets. Box plots depict median \pm
 463 IQR, KW=Kruskal-Wallis, Mann-Whitney U-test $*p<0.05$, $**p<0.01$.

464



465

466 **Figure 3.** Stratification of physiologic impairment according to American Thoracic Society criteria. The
 467 severity of impairment of (A) FVC and (B) DLCO for IIM and SSc subsets are shown.

Table 1. Clinical manifestations of various myositis specific and associated autoantibodies

	Autoantibody	Clinical features	Frequency of organ involvement		
			Skin	Muscle	Lung
Anti-tRNA synthetase syndrome	Jo-1 [3, 25]	Classic dermatomyositis with typical rash, muscle weakness, ILD, and mechanic's hands	30-58%	69.3-86%	68%-95%
	PL-7 [3, 25]	Hypomyopathic myositis with frequent arthritis, mechanic's hands, and ILD	29-56%	40-81%	>90%
	PL-12 [3, 25]		29-70%	40-69%	>90%
	OJ [26]		0%	57%	100%
	EJ [27-29]		0-75%	0-100%	50-100%
Other myositis specific autoantibodies	Mi-2 [30]	Classical rash with mild to moderate muscle involvement, ILD uncommon	90%	100%	7%
	NXP-2 [31, 32]	Mild to moderate muscle involvement with myalgia, dysphagia, classical skin rashes, increased malignancy risk, can be associated with ILD	17-32%	>95%	7-25%
	TIF-1 γ [33]	Marked skin involvement often with ulceration, muscle weakness, dysphagia, malignancy	>90%	63%	9.1%
	SAE [34]	Classic skin rashes associated with mild to moderate weakness, ILD uncommon	>80%	>95%	18%
	SRP [35]	Necrotizing myopathy with marked weakness, minimal skin involvement, and infrequent ILD	3%	>90%	22%
	MDA5 [36]	Frequent and severe ILD with minimal or no muscle involvement and classically ulcerative skin lesions or palmar papules.	87.5%	50%	50%
Overlap syndrome autoantibodies	Ku [37]	Overlap syndrome of systemic sclerosis and inflammatory myositis with mild muscle/skin involvement and variable ILD severity	n.r.	30%	43%
	U1RNP [38]	Overlap syndrome of systemic lupus, systemic sclerosis, and inflammatory myositis	60%	80%	45%
	U3RNP [39]	Diffuse systemic sclerosis with increased frequency of inflammatory myopathy	>95%	25%	61%
	Pm/ScI [40]	Mild myositis and/or systemic sclerosis features frequently with ILD	85%	38%	61%
Abbreviations: ILD=interstitial lung disease					

*ILD more common in patients with inflammatory myositis compared to other Ku positive patients

Table 2. Demographics

	Idiopathic Inflammatory Myopathies (n=77)	Systemic Sclerosis (n=47)	p value
Age (years)[†]	57.7(48.4,66.7)	62.3(52.3,69.0)	.013
Female Gender	60 (77.9%)	37 (78.7%)	1.00
Race			
Caucasian	63 (81.8%)	37 (78.7%)	0.82
African American	11 (14.2%)	7 (14.9%)	1.00
Other	3 (3.9%)	3 (6.4%)	0.67
Disease Duration (years)[†]	5.2(2.4,10.4)	9.5(4.8,14.6)	0.007
Known Presence of ILD	40 (51.9%)	28 (59.5%)	0.46
Radiographic and physiologic evidence of ILD	33/40 (82.5%)	20/28 (71.4%)	0.37
Radiographic evidence of ILD with normal PFTs	2/40 (5.0%)	1/28 (3.6%)	1.00
Physiologic evidence of ILD with normal imaging	5/40 (12.5%)	6/28 (21.4%)	0.34
Historic documentation without objective data	0/40	1/28 (3.6%)	1.00
Known Presence of Pulmonary Hypertension	8 (20%)	17 (36.1%)	0.001
Pulmonology as First Point of Care at VUMC	22 (28.5%)	13 (27.6%)	1.00
[†] reported as median (interquartile range)			
Abbreviations: ILD=interstitial lung disease, PFTs=pulmonary function tests, VUMC=Vanderbilt University Medical Center			

Table 3. Clinical Phenotype of Idiopathic Inflammatory Myopathies Patients

	Associated Serologies			Cutaneous Manifestations		Muscle Involvement		Arthritis	Dysphagia	Raynaud's
	ANA	RF	Ro52	Gottron's or Heliotrope Rash	Mechanic's Hands	Proximal Muscle Weakness	Muscle Enzyme Elevation		or GERD	Phenomenon
By Clinical Phenotype*										
Dermatomyositis (n=37)	25/31 (80.6%)	4/17 (23.5%)	8/12 (40.0%)	33/37 (89.1%)	9/37 (24.3%)	27/37 (73.0%)	29/37 (78.3%)	10/37 (27.0%)	11/37 (29.8%)	14/37 (37.8%)
Polymyositis (n=12)	6/10 (60.0%)	2/5 (40.0%)	0/6 (0%)	0/12 (0%)	0/12 (0%)	12/12 (100%)	11/12 (91.7%)	1/12 (8.3%)	8/12 (66.7%)	2/12 (16.7%)
Anti-Synthetase Syndrome (n=28)	9/25 (36.0%)	4/21 (19.0%)	14/22 (63.6%)	6/28 (21.4%)	12/28 (43.8%)	18/28 (64.3%)	21/28 (75.0%)	17/28 (60.7%)	13/28 (46.4%)	10/28 (35.7%)
By Serology										
Jo-1 (n=14)	3/11 (27.2%)	2/10 (20%)	5/9 (55.6%)	2/14 (14.3%)	8/14 (57.1%)	12/14 (85.6%)	12/14 (85.6%)	13/14 (92.9%)	7/14 (50%)	6/14 (42.9%)
PL-7 (n=5)	2/5 (40.0%)	1/5 (20.0%)	3/5 (60.0%)	1/5 (20.0%)	2/5 (40.0%)	2/5 (60.0%)	2/5 (40.0%)	1/5 (20.0%)	3/5 (60.0%)	1/5 (20.0%)
PL-12 (n=6)	1/5 (20.0%)	1/4 (14.3%)	4/6 (42.9%)	3/6 (50.0%)	1/1 (16.7%)	3/6 (50.0%)	5/6 (83.3%)	1/6 (16.7%)	3/6 (50.0%)	2/6 (33.3%)
EJ (n=1)	0/1 (0%)	0/0 (0%)	1/1 (100%)	0/1 (0%)	0/1 (0%)	0/1 (0%)	1/1 (100%)	1/1 (100%)	1/1 (100%)	0/1 (0%)
OJ (n=2)	1/2 (50.0%)	0/0 (0%)	1/1 (100%)	0/2 (0%)	1/2 (50.0%)	1/2 (50.0%)	1/2 (50.0%)	1/2 (50.0%)	1/2 (50.0%)	1/2 (50.0%)
Ku	2/2	0/1	2/2	1/2	0/2	1/2	2/2	0/2	1/2	0/2

(n=2)	(100%)	(0%)	(100%)	(50.0%)	(0%)	(50.0%)	(100%)	(0%)	(50.0%)	(0%)
NXP	3/3	0/2	1/2	2/3	0/3	2/3	3/3	0/3	1/3	0/3
(n=3)	(100%)	(0%)	(50.0%)	(66.7%)	(0%)	(66.7%)	(100.0%)	(0%)	(33.3%)	(0%_
TIF1g	1/1	0/0	0/1	1/1	0/1	1/1	1/1	0/1	1/1	0/1
(n=1)	(100%)	(0%)	(0%)	(100%)	(0%)	(100%)	(50.0%)	(0%)	(100%)	(0%)
Pm/Scl	4/4	2/2	2/4	3/4	3/4	4/4	4/4	2/4	3/4	0/4
(n=4)	(100%)	(100%)	(50.0%)	(75.0%)	(75.0%)	(100%)	(100%)	(50.0%)	(75.0%)	(0%)
SRP	0/2	0/1	0/2	0/2	0/2	2/2	2/2	0/2	2/2	0/2
(n=2)	(0%)	(0%)	(0%)	(0%)	(0%)	(100%)	(100%)	(0%)	(100%)	(0%)
Mi2	5/5	0/1	1/3	5/5	2/5	5/5	5/5	1/5	1/5	3/5
(n=5)	(100%)	(0%)	(33.3%)	(100%)	(40.0%)	(100.0%)	(10.0%)	(20%)	(20%)	(40%)

*These are non-overlapping phenotypes. All patients with anti-tRNA synthetase antibodies were categorized as anti-synthetase syndrome.

Abbreviations: ANA=anti-nuclear antibodies, RF=rheumatoid factor, GERD=gastroesophageal reflux disease

Table 4. Comprehensive myositis serologies play a critical role in the serologic detection of ARS-ILD compared to other IIM-ILD

	+ANA	+RF	+CCP	Diagnostic yield after initial serologic work-up	Diagnostic yield after testing CK level	Diagnostic yield after adding MSA/MAA [†]
Dermatomyositis (n=15)	11/12 (86.7%)	3/6 (50.0%)	2/4 (50.0%)	13/15 (86.7%)	13/15 (86.7%)	13/15 (86.7%)
Polymyositis (n=3)	1/3 (33.3%)	1/3 (33.3%)	1/2 (50%)	1/3 (33.3%)	3/3 (100%)	3/3 (100%)
Anti-synthetase Syndrome (n=22)	5/20 (25.0%)	4/18 (22.2%)	0/13 (0%)	7/21 (33.3%)	16/22 (72.7%)	22/22 (100%)

† MSA = myositis specific antibodies (Jo-1, PL-7, PL-12, OJ, EJ, Mi-2, SRP, TIF-1γ, MJ/NXP-2, SAE, MDA-5/CADM-140; MAA = myositis associated antibodies (Pm/Scl, Ku, U1RNP, U3RNP, Ro52)

Abbreviations: ARS-ILD=anti-tRNA synthetase related interstitial lung disease, IIM-ILD idiopathic inflammatory myopathies associated interstitial lung disease, ANA=anti-nuclear antibodies, RF=rheumatoid factor, CCP=anti-cyclic citrullinated peptide, CK=creatinine kinase,

Table 5. Radiographic features of interstitial lung disease in patients with IIM compared to SSc

	Radiographic Characteristics			
	UIP	GGO	BC	HC
Inflammatory Myositis				
Dermatomyositis (n=15)	1/13 (7.7%)	10/13 (76.9%)	4/13 (30.8%)	1/13 (7.7%)
Polymyositis (n=3)	0/3 (0%)	2/3 (66.7%)	0/3 (0%)	0/3 (0%)
Anti-Synthetase Syndrome (n=22)	5/22 (22.7%)	12/22 (54.5%)	11/22 (50%)	3/22 (13.6%)
By Serology				
Jo-1 (n=10)	2/10 (20%)	9 (90%)	7/10 (70.0%)	12 (20.0%)
PL-7 (n=5)	1 (20%)	3 (60%)	4 (80%)	3 (60%)
PL-12 (n=5)	1 (20.0%)	4 (80%)	4 (80%)	1 (20%)
EJ (n=1)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
OJ (n=1)	0 (0%)	1 (100%)	0 (0%)	0 (0%)
Ku (n=2)	0 (0%)	1/2 (50%)	0 (0%)	0 (0%)
NXP (n=1)	0 (0%)	1 (100%)	1 (100%)	0 (0%)
Pm/Scl (n=3)	0 (0%)	3/3 (100%)	1/3 (33.3%)	0 (0%)
SRP (n=1)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mi2 (n=1)	0 (0%)	1 (100%)	1 (100%)	0 (0%)
Systemic Sclerosis				

lcSSc	3/15	9/15	8/15	5/15
(n=18)	(20%)	(60%)	(53.3%)	(33.3%)
dcSSc	1/9	8/9	6/9	5/9
(n=10)	(11.1%)	(88.9%)	(66.7%)	(55.6%)

Abbreviations: IIM=idiopathic inflammatory myopathies,

SSc=systemic sclerosis, UIP = usual interstitial pneumonia (definite or probable), GGO = ground glass opacities, BC = bronchiectasis,

HC = honeycomb changes, lcSSc=limited cutaneous systemic

sclerosis, dcSSc=diffuse cutaneous systemic sclerosis